BAP1, PROGNOSTIC BIOMARKER IN GLIOBLASTOMA?
DOI:
https://doi.org/10.61229/mpj.v1i1.8Keywords:
biomarker, glioblastoma, BAP1Abstract
A longer time to diagnosis determines a poor prognosis in cancer patients, mainly in aggressive brain tumors, such as glioblastoma (GBM), determining an average 1-year survival in 30% of cases. In this context, the biomarkers research for early detection and prognostic evaluation is very important to improve outcomes of GBM patients. The present study is a narrative literature review. We analyzed 33 articles, selected between the years 2007 and 2022, considering the BAP1 protein and its relationship with the establishment of GBM neoplasms. The BAP1 gene, located on 3p21.1 locus, encodes the primary catalytic domain of the BAP1 protein, which removes ubiquitin signals from protein substrates. BAP1 acts in many cell signaling pathways that regulate the tumors establishment, such as cell death, cell cycle control and proliferation, DNA damage response, and chromatin modification. Although BAP1 has been considered a candidate tumor biomarker for prognosis response in different types of tumors, further investigations are necessary to determine these target interactions and their role as a biomarker in central nervous system tumors, including GBM.
Downloads
References
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. junho de 2016;131(6):803–20. DOI: https://doi.org/10.1007/s00401-016-1545-1
Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. setembro de 2021;71(5):381–406. DOI: https://doi.org/10.3322/caac.21693
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. novembro de 2018;68(6):394–424. DOI: https://doi.org/10.3322/caac.21492
Broekman ML, Maas SLN, Abels ER, Mempel TR, Krichevsky AM, Breakefield XO. Multidimensional communication in the microenvirons of glioblastoma. Nat Rev Neurol. agosto de 2018;14(8):482–95. DOI: https://doi.org/10.1038/s41582-018-0025-8
Câncer do sistema nervoso central [Internet]. Instituto Nacional de Câncer - INCA. [citado 31 de outubro de 2022]. Disponível em: https://www.gov.br/inca/pt-br/assuntos/cancer/tipos/sistema-nervoso-central
Alexander BM, Cloughesy TF. Adult Glioblastoma. J Clin Oncol. 20 de julho de 2017;35(21):2402–9. DOI: https://doi.org/10.1200/JCO.2017.73.0119
E LR, M P, P R, Da R, M van den B, P W, et al. Molecular targeted therapy of glioblastoma. Cancer treatment reviews [Internet]. novembro de 2019 [citado 31 de outubro de 2022];80. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31541850/ DOI: https://doi.org/10.1016/j.ctrv.2019.101896
Watts C, Sanai N. Surgical approaches for the gliomas. Handb Clin Neurol. 2016;134:51–69. DOI: https://doi.org/10.1016/B978-0-12-802997-8.00004-9
Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of Brain Tumors. Neurol Clin. agosto de 2018;36(3):395–419. DOI: https://doi.org/10.1016/j.ncl.2018.04.001
Ou A, Yung WKA, Majd N. Molecular Mechanisms of Treatment Resistance in Glioblastoma. Int J Mol Sci. 31 de dezembro de 2020;22(1):E351. DOI: https://doi.org/10.3390/ijms22010351
Carrasco-Garcia E, Sampron N, Aldaz P, Arrizabalaga O, Villanua J, Barrena C, et al. Therapeutic strategies targeting glioblastoma stem cells. Recent Pat Anticancer Drug Discov. setembro de 2013;8(3):216–27. DOI: https://doi.org/10.2174/15748928113089990002
Louie BH, Kurzrock R. BAP1: Not just a BRCA1-associated protein. Cancer Treat Rev. novembro de 2020;90:102091. DOI: https://doi.org/10.1016/j.ctrv.2020.102091
Wang A, Papneja A, Hyrcza M, Al-Habeeb A, Ghazarian D. Gene of the month: BAP1. J Clin Pathol. setembro de 2016;69(9):750–3. DOI: https://doi.org/10.1136/jclinpath-2016-203866
Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology. fevereiro de 2013;45(2):116–26. DOI: https://doi.org/10.1097/PAT.0b013e32835d0efb
Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature. 13 de maio de 2010;465(7295):243–7. DOI: https://doi.org/10.1038/nature08966
Campagne A, Lee MK, Zielinski D, Michaud A, Le Corre S, Dingli F, et al. BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation. Nat Commun. 21 de janeiro de 2019;10(1):348. DOI: https://doi.org/10.1038/s41467-018-08255-x
Wu J, Lu LY, Yu X. The role of BRCA1 in DNA damage response. Protein Cell. fevereiro de 2010;1(2):117–23. DOI: https://doi.org/10.1007/s13238-010-0010-5
Meas R, Mao P. Histone ubiquitylation and its roles in transcription and DNA damage response. DNA Repair (Amst). dezembro de 2015;36:36–42. DOI: https://doi.org/10.1016/j.dnarep.2015.09.016
Nishikawa H, Wu W, Koike A, Kojima R, Gomi H, Fukuda M, et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res. 1o de janeiro de 2009;69(1):111–9. DOI: https://doi.org/10.1158/0008-5472.CAN-08-3355
Ismail IH, Davidson R, Gagné JP, Xu ZZ, Poirier GG, Hendzel MJ. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res. 15 de agosto de 2014;74(16):4282–94. DOI: https://doi.org/10.1158/0008-5472.CAN-13-3109
Yu H, Pak H, Hammond-Martel I, Ghram M, Rodrigue A, Daou S, et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci U S A. 7 de janeiro de 2014;111(1):285–90. DOI: https://doi.org/10.1073/pnas.1309085110
Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem. 4 de dezembro de 2009;284(49):34179–88. DOI: https://doi.org/10.1074/jbc.M109.046755
Tyagi S, Chabes AL, Wysocka J, Herr W. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol Cell. 6 de julho de 2007;27(1):107–19. DOI: https://doi.org/10.1016/j.molcel.2007.05.030
Pan H, Jia R, Zhang L, Xu S, Wu Q, Song X, et al. BAP1 regulates cell cycle progression through E2F1 target genes and mediates transcriptional silencing via H2A monoubiquitination in uveal melanoma cells. Int J Biochem Cell Biol. março de 2015;60:176–84. DOI: https://doi.org/10.1016/j.biocel.2015.01.001
Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, et al. BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature. 22 de junho de 2017;546(7659):549–53. DOI: https://doi.org/10.1038/nature22798
Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. outubro de 2018;20(10):1181–92. DOI: https://doi.org/10.1038/s41556-018-0178-0
Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med. 18 de fevereiro de 2019;11(1):8. DOI: https://doi.org/10.1186/s13073-019-0620-3
Ladanyi M, Sanchez Vega F, Zauderer M. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. Genome Med. 26 de março de 2019;11(1):18. DOI: https://doi.org/10.1186/s13073-019-0631-0
Bonilla B, Hengel SR, Grundy MK, Bernstein KA. RAD51 Gene Family Structure and Function. Annu Rev Genet. 23 de novembro de 2020;54:25–46. DOI: https://doi.org/10.1146/annurev-genet-021920-092410
Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 1o de setembro de 2008;68(17):6953–62. DOI: https://doi.org/10.1158/0008-5472.CAN-08-0365
Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. junho de 2016;73(11–12):2195–209. DOI: https://doi.org/10.1007/s00018-016-2194-1
Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). fevereiro de 2018;243(3):213–21. DOI: https://doi.org/10.1177/1535370217750088
M C, Se M, Ja J, F GS, A C, S D. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology. Cancer cytopathology [Internet]. dezembro de 2020;128(12). DOI: https://doi.org/10.1002/cncy.22326
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Mário Penna Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
- Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade.
- Declaro, ainda, que uma vez publicado na revista Mário Penna Journal, editada pelo Instituto Mário Penna, o mesmo jamais será submetido por mim ou por qualquer um dos demais co-autores, caso haja, a qualquer outro periódico.
- Por meio deste instrumento, em meu nome e em nome dos demais co-autores, porventura existentes, cedo os direitos autorais do referido artigo ao Instituto Mário Penna e declaro estar ciente de que a não observância deste compromisso submeterá o infrator a sanções e penas previstas na Lei de Proteção de Direitos Autorias (Nº9609, de 19/02/98).
A Revista Mário Penna Journal é licenciada sob uma licença Creative Commons Atribuição-NãoComercial-CompartilhaIgual 4.0 Internacional
